Achiko Logo cropped.jpg
Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by June 26, 2022
20 juin 2022 20h24 HE | Achiko AG
ZURICH, Switzerland, June 20, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that...
Achiko Logo cropped.jpg
Achiko AG Obtains CE Mark for AptameX™ Covid-19 Rapid Test
17 mai 2022 07h30 HE | Achiko AG
Registered AptameX and Has Obtained a CE Mark, Allowing the Product to Be Sold in 27 Countries in the EUAptameX Has Unique Performance Advantages Over Other Rapid Tests Through its Use of DNA...
Achiko Logo cropped.jpg
Achiko AG Signs Major Marketing and Sales Agreement with World’s Largest Islamic Association for its AptameX Covid-19 Rapid Test
20 avr. 2022 07h45 HE | Achiko AG
Signed major deal with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta, for the use of Covid-19 test AptameX in general assemblies and activities. Located primarily in Indonesia, Nahdlatul Ulama is the...
Achiko Logo cropped.jpg
Achiko Secures up to USD$12.6 Million Equity and Debt Financing Lines with RiverFort Over Three Years
20 avr. 2022 07h30 HE | Achiko AG
ZURICH, Switzerland, April 20, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces the...
Achiko Logo cropped.jpg
Achiko AG Production and Sales Update
03 mars 2022 07h30 HE | Achiko AG
Unique Chemistry with DNA Aptamers Completing Pre-Sales Validation TestingCompleting Pre-Sales Validation Testing in Indonesia ZURICH, Switzerland, March 03, 2022 (GLOBE NEWSWIRE) -- Ad...
Achiko Logo cropped.jpg
Achiko’s Commercialization Update: Optimized Second-Generation Covid-19 Diagnostic Test Receives Full Product Registration Approval in Indonesia
08 déc. 2021 07h50 HE | Achiko AG
Second-generation of AptameX, Achiko’s innovative DNA aptamer diagnostic test for Covid-19 has received full approval in Indonesia for five yearsProduction of the second-generation AptameX kits to...
Achiko Logo cropped.jpg
Achiko’s Covid-19 DNA Aptamer-Based Rapid Testing Platform Update
24 nov. 2021 07h30 HE | Achiko AG
Pilot program in Indonesia is on track with positive results and support for Achiko’s proprietary, low-cost rapid Covid-19 diagnostic test, AptameX, alongside its sister digital passporting service...
Achiko Logo cropped.jpg
Market Outlook and Production Plan Update for AptameX
20 oct. 2021 07h30 HE | Achiko AG
After receiving product and registration approval from Indonesia’s Ministry of Health in August, Achiko is positioned to produce up to a million AptameX test kits in Q4 2021, and more if the supply...
Achiko Logo cropped.jpg
Achiko’s Rapid Covid-19 Diagnostic Test AptameX™ Receives Product and Registration Approval from Indonesia’s Ministry of Health
25 août 2021 07h30 HE | Achiko AG
AptameX™, Achiko’s breakthrough DNA aptamer-based diagnostic test for Covid-19, received product and registration emergency use approval from the Ministry of Health in Indonesia, alongside its sister...
Achiko Logo cropped.jpg
Achiko Engages EpiMetrics to Expand Covid-19 Testing Operations with Udayana University in Bali, Indonesia in the Implementation of a Mass Testing Program
15 juil. 2021 07h30 HE | Achiko AG
ZURICH, Switzerland, July 15, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), a global healthtech company...